Biossil
Biossil is a drug development company founded with the mission to develop targeted therapies for biologically defined sub-groups, focusing on diseases where population variability challenges traditional drug discovery. They aim to structurally compress the time and cost required to bring new therapies to market. The company highlights its substantial assets, with over $1B USD in cost base and a significant number of development programs (11) and supporting manuscripts (29). Their team includes 18 individuals with MDs and PhDs leading development and over 30 million relational embeddings.
Biossil
Biossil is a drug development company founded with the mission to develop targeted therapies for biologically defined sub-groups, focusing on diseases where population variability challenges traditional drug discovery. They aim to structurally compress the time and cost required to bring new therapies to market. The company highlights its substantial assets, with over $1B USD in cost base and a significant number of development programs (11) and supporting manuscripts (29). Their team includes 18 individuals with MDs and PhDs leading development and over 30 million relational embeddings.